摘要
目的：探讨经导管动脉化疗栓塞术（ TACE）对原发性肝癌患者外周循环肿瘤细胞（ CTC）数量及血管内皮生长因子（ VEGF）浓度的影响。方法选择2011年至2013年50例原发性肝癌患者为研究对象，应用免疫磁珠分离技术及酶联免疫吸附法检测在TACE术前1天及术后1天、3天、30天CTC数量和VEGF浓度的变化。结果 TACE术前1天和术后1天、3天、30天的CTC阳性率分别为84.0％和66.0％、58.0％、78.0％，CTC检测数量分别为（2.38±1.65）个、（1.24±1.06）个、（0.86±0.83）个、（2.10±1.63）个，手术前后比较差异均有统计学意义（P＜0.05）；术前1天及术后1天、3天、30天的VEGF浓度分别为（304.98±33.94） pg／ml、（262.93±28.22） pg／ml、（258.40±27.55） pg／ml、（283.08±37.19） pg／ml，手术前后比较差异有统计学意义（ P＜0.05）。对CTC数量及VEGF浓度在术后30天与术后3天两时段的差值进行相关分析，两者呈线性正相关（ r＝0.710，P＜0.05）。结论 TACE治疗原发性肝癌术后1∽3天内可以有效减少血液VEGF浓度并阻止肿瘤细胞进入外周血循环。
Objective To investigate the effect of transcatheter arterial chemoembolization （ TACE ） treatment on the circulating tumor cell（ CTC） number and the serum vascular endothelial growth fator（ VEGF） concentration in patients with primary liv.er cancer（ PLC） . Methods Totally fifty patients with primary PLC were select from the First Affiliated Hospital of Baotou Medical College between 2011 and 2013.The CTC number and VEGF concentration on day 1 before TACE, as well as day 1, day 3 and day 30 after TACE were measured by immunomagnetic beadssparation techniques（IMBS） and enzyme.linked immunosorbent assay（ELISA）. Results The positive rates of CTC on day 1 before TACE, as well as day 1, day 3 and day 30 after TACE were 84.0%, 66.0%, 58.0% and 78.0%, respectively. The CTC numbers were 2.38 ± 1.65, 1.24 ± 1.06, 0.86 ± 0.83, 2.10 ± 1.63, respectively. The difference was statistically significant before and after TACE （ P〈0.05） . The concentration of VEGF on day 1 before TACE, as well as on day 1, day 3 and day 30 after TACE were （304.98±33.94） pg/ml and （262.93±28.22） pg/ml,（258.40±27.55） pg/ml, （283.08±37.19） pg/ml. The difference was statistically significant before and after TACE （P〈0.05）. Conclusion The VEGF con.centration and CTC number will reduce within 1.3 days after TACE in patients with PLC.
出处
《临床肿瘤学杂志》
CAS
2015年第8期709-712,共4页
Chinese Clinical Oncology
基金
内蒙古教育厅2014年支持项目(NJZC14260)
包头市医药卫生2014支持项目(BTYW20140218)
关键词
原发性肝癌
经导管动脉化疗栓塞术(TACE)
外周循环肿瘤细胞
血管内皮生长因子
Primary liver cancer （ PLC ）
Transcatheter arterial chemoembolization （ TACE ）
Circulating tumor cell（CTC）
Vascular endothelial growth factor（VEGF）
